MAP2K7 and melanoma: Selective targeting of the BRAF or MEK kinases using targeted small-molecule inhibitory drugs in patients with BRAF V600E mutant melanoma has been associated with impressive clinical responses in more than half of treated patients - despite the presence of systemic disease [2,3].